RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research (Q36836615)

16 August 2017

1 reference

title

RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research (English)

1 reference

16 August 2017

1 reference

Hong Chang

1

1 reference

16 August 2017

1 June 2007

1 reference

16 August 2017

1 reference

16 August 2017

14

1 reference

16 August 2017

8

1 reference

16 August 2017

677-685

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7701063

16 August 2017

0 references

cites work

A role for survivin in radioresistance of pancreatic cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Surgery for pancreatic cancer: recent controversies and current practice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

1 reference

7 January 2021

The genetics of pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Genomics of pancreatic cancer: does it make any improvement in diagnosis, prognosis and therapy?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Focus on pancreas cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Molecular pathology of pancreatic cancer: in quest of tumor suppressor genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Breakthrough of the year. Small RNAs make big splash

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Short interfering RNAs as a tool for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Role for a bidentate ribonuclease in the initiation step of RNA interference

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

RNA interference and potential therapeutic applications of short interfering RNAs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

The prospect of silencing disease using RNA interference

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

BRAF and K-ras gene mutations in human pancreatic cancers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Stable suppression of tumorigenicity by virus-mediated RNA interference

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Expression of CEACAM6 in Resectable Colorectal Cancer: A Factor of Independent Prognostic Significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Tissue factor expression correlates with histological grade in human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

EphA2 expression is associated with aggressive features in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Expression and localization of GLUT1 and GLUT12 in prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Mechanisms of taxotere-related drug resistance in pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Apoptosis: targets in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Strategies for inhibition of MDR1 gene expression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Reversal of P-glycoprotein-mediated multidrug resistance with small interference RNA (siRNA) in leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Detection of anti-livin antibody in gastrointestinal cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Survivin expression is a prognostic marker in pancreatic cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Isoform-specific silencing of the Livin gene by RNA interference defines Livin beta as key mediator of apoptosis inhibition in HeLa cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Characterisation of integrin-linked kinase signalling in sporadic human colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Expression of integrin-linked kinase is closely correlated with invasion and metastasis of gastric carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xe

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

The role of focal-adhesion kinase in cancer - a new therapeutic opportunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

RNA interference: from gene silencing to gene-specific therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

RNA interference-based functional genomics in cancer research--an introduction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

RNA-interference-based functional genomics in mammalian cells: reverse genetics coming of age.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Gene therapy developments for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701063

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7701063

1 reference

16 August 2017

1 reference

PubMed ID

17541422